Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06799039
EARLY_PHASE1
Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease
Sponsor: Brigham and Women's Hospital
View on ClinicalTrials.gov
Summary
This 3+3 dose escalation pilot trial will assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in the Inflammatory Bowel Disease (IBD) patient population.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
69
Start Date
2026-09-01
Completion Date
2031-09-01
Last Updated
2025-12-16
Healthy Volunteers
No
Interventions
DRUG
Xylitol
Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Patients will be consecutively enrolled into one of five dosing including 1g, 2g, 5g, 7g and 9g.
Locations (1)
Brigham and Women's Hospital
Boston, Massachusetts, United States